文献速递中医内科中药与中成药合理使用

通心络胶囊用于ST段抬高型心肌梗死二级预防的系统评价与荟萃分析

Tongxinluo capsules for secondary prevention after ST-segment elevation myocardial infarction: A systematic review and meta-analysis.
PubMed 文献 · J Ethnopharmacol · 2025-01-27

该系统评价纳入10项随机对照试验共4690例STEMI患者,评价通心络胶囊联合常规治疗用于二级预防的疗效与安全性。结果显示联合通心络可降低主要不良心脑血管事件发生率(RR=0.61,95%CI 0.51–0.73,P<0.00001)并改善心功能(MD=4.95,95%CI 3.26–6.64,P<0.00001),不良事件发生率与对照组无统计学差异,证据确定性为中至低。

要点

  • 通心络联合常规治疗可降低STEMI患者MACCEs风险(RR=0.61)。
  • 联合通心络可改善STEMI患者心功能(MD=4.95)。
  • 不良事件发生率与对照组无统计学差异,证据确定性中至低。

核心结论

  • 通心络胶囊可能对STEMI患者主要不良心脑血管事件具有预防作用,但真实世界中的疗效与安全性尚需进一步实践确认。

研究设计与样本

  • 系统评价与荟萃分析,检索7个电子数据库至2024年5月10日的随机对照试验,最终纳入10项RCT共4690例STEMI患者。

主要发现

  • 与单用常规治疗相比,通心络联合常规治疗降低MACCEs发生率(RR=0.61,95%CI 0.51–0.73,P<0.00001)。
  • 通心络联合常规治疗改善心功能(MD=4.95,95%CI 3.26–6.64,P<0.00001)。
  • 通心络组与对照组不良事件发生率无统计学显著差异。
  • 证据确定性评价为中至低。

关键数值与推荐

  • MACCEs风险比RR=0.61(95%CI 0.51–0.73,P<0.00001),对象为STEMI患者接受通心络联合常规治疗对比单用常规治疗。
  • 心功能改善均值差MD=4.95(95%CI 3.26–6.64,P<0.00001),对象同上。
  • 证据确定性为中至低。

临床怎么用

  • 在STEMI患者二级预防中,可考虑在常规治疗基础上联合通心络胶囊以降低MACCEs风险并改善心功能。
  • 临床决策需结合证据确定性中至低及真实世界数据尚待确认的背景。

局限性

  • 纳入研究数量有限(10项RCT),证据确定性评价为中至低。
  • 真实世界环境下的疗效与安全性需未来实践进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Tongxinluo (TXL), a Chinese patent medicine, is commonly used for secondary prevention of cardiovascular events. AIM OF THE STUDY: To evaluate the efficacy and safety of TXL for secondary prevention after ST-segment elevation myocardial infarction (STEMI). MATERIALS AND METHODS: A search for relevant randomized controlled trials (RCTs) was conducted across seven electronic databases from inception to May 10, 2024. Two independent reviewers conducted trial selection, data collection, and bias assessment. We performed a meta-analysis of efficacy and safety outcomes, and assessed the quality of evidence. RESULTS: Ten RCTs were included, involving 4690 patients with STEMI. Compared to conventional treatments (CTs) alone, TXL combined with CTs reduced the incidence of major adverse cardiac and cerebrovascular events (MACCEs) in patients with STEMI (risk ratio [RR] = 0.61, 95 % confidence interval [CI] 0.51 to 0.73, P < 0.00001). TXL also contributed to improving cardiac function (mean difference [MD] = 4.95, 95 % CI 3.26 to 6.64, P < 0.00001). Furthermore, no statistically significant difference was observed in the incidence of adverse events between the TXL and control groups. The certainty of evidence was evaluated as moderate to low. CONCLUSION: TXL might provide preventive effects against MACCEs for patients with STEMI. However, the efficacy and safety of TXL for secondary prevention in real-world settings require further confirmation through future practice.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Wang L, Cui Z, et al. Tongxinluo capsules for secondary prevention after ST-segment elevation myocardial infarction: A systematic review and meta-analysis. J Ethnopharmacol. 2025. PMID: 39880063. doi:10.1016/j.jep.2025.119419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。